Cargando…

Evaluation of commercial devices for patient specific QA of stereotactic radiotherapy plans

Stereotactic radiotherapy (SRT) methods have become common for the treatment of small tumors in various parts of the body. Small field dosimetry has a unique set of challenges when it comes to the pre‐treatment validation of a radiotherapy plan that involves film dosimetry or high‐resolution detecto...

Descripción completa

Detalles Bibliográficos
Autores principales: James, Shands, Al‐Basheer, Ahmad, Elder, Eric, Huh, Chulhaeng, Ackerman, Christopher, Barrett, John, Hamilton, Russell, Mostafaei, Farshad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402672/
https://www.ncbi.nlm.nih.gov/pubmed/37158727
http://dx.doi.org/10.1002/acm2.14009
_version_ 1785084894389469184
author James, Shands
Al‐Basheer, Ahmad
Elder, Eric
Huh, Chulhaeng
Ackerman, Christopher
Barrett, John
Hamilton, Russell
Mostafaei, Farshad
author_facet James, Shands
Al‐Basheer, Ahmad
Elder, Eric
Huh, Chulhaeng
Ackerman, Christopher
Barrett, John
Hamilton, Russell
Mostafaei, Farshad
author_sort James, Shands
collection PubMed
description Stereotactic radiotherapy (SRT) methods have become common for the treatment of small tumors in various parts of the body. Small field dosimetry has a unique set of challenges when it comes to the pre‐treatment validation of a radiotherapy plan that involves film dosimetry or high‐resolution detectors. Comparison of commercial quality assurance (QA) devices to the film dosimetry method for pre‐treatment evaluation of stereotactic radiosurgery (SRS), fractionated SRT, and stereotactic body radiation therapy treatment plans have been evaluated in this study. Forty stereotactic QA plans were measured using EBT‐XD film, IBA Matrixx Resolution, SNC ArcCHECK, Varian aS1200 EPID, SNC SRS MapCHECK, and IBA myQA SRS. The results of the commercial devices are compared to the EBT‐XD film dosimetry results for each gamma criteria. Treatment plan characteristics such as modulation factor and target volume were investigated for correlation with the passing rates. It was found that all detectors have greater than 95% passing rates at 3%/3 mm. Passing rates decrease rapidly for ArcCHECK and the Matrixx as criteria became more strict. In contrast, EBT‐XD film, SNC SRS MapCHECK, and IBA myQA SRS passing rates do not decline as rapidly when compared to Matrix Resolution, ArcCHECK, and the EPID. EBT‐XD film, SNC SRS MapCHECK, and IBA myQA SRS maintain greater than 90% passing rate at 2%/1 mm and greater than 80% at 1%/1 mm. Additionally, the ability of these devices to detect changes in dose distribution due to MLC positioning errors was investigated. Ten VMAT SBRT/SRS treatment plans were created with 6 MV FFF or 10 MV FFF beam energies using Eclipse 15.6. A MATLAB script was used to create two MLC positioning error scenarios from the original treatment plan. It was found that errors in MLC positioning were most reliably detected at 2%/1 mm for high‐resolution detectors and that lower‐resolution detectors did not consistently detect MLC positioning errors.
format Online
Article
Text
id pubmed-10402672
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-104026722023-08-05 Evaluation of commercial devices for patient specific QA of stereotactic radiotherapy plans James, Shands Al‐Basheer, Ahmad Elder, Eric Huh, Chulhaeng Ackerman, Christopher Barrett, John Hamilton, Russell Mostafaei, Farshad J Appl Clin Med Phys Radiation Oncology Physics Stereotactic radiotherapy (SRT) methods have become common for the treatment of small tumors in various parts of the body. Small field dosimetry has a unique set of challenges when it comes to the pre‐treatment validation of a radiotherapy plan that involves film dosimetry or high‐resolution detectors. Comparison of commercial quality assurance (QA) devices to the film dosimetry method for pre‐treatment evaluation of stereotactic radiosurgery (SRS), fractionated SRT, and stereotactic body radiation therapy treatment plans have been evaluated in this study. Forty stereotactic QA plans were measured using EBT‐XD film, IBA Matrixx Resolution, SNC ArcCHECK, Varian aS1200 EPID, SNC SRS MapCHECK, and IBA myQA SRS. The results of the commercial devices are compared to the EBT‐XD film dosimetry results for each gamma criteria. Treatment plan characteristics such as modulation factor and target volume were investigated for correlation with the passing rates. It was found that all detectors have greater than 95% passing rates at 3%/3 mm. Passing rates decrease rapidly for ArcCHECK and the Matrixx as criteria became more strict. In contrast, EBT‐XD film, SNC SRS MapCHECK, and IBA myQA SRS passing rates do not decline as rapidly when compared to Matrix Resolution, ArcCHECK, and the EPID. EBT‐XD film, SNC SRS MapCHECK, and IBA myQA SRS maintain greater than 90% passing rate at 2%/1 mm and greater than 80% at 1%/1 mm. Additionally, the ability of these devices to detect changes in dose distribution due to MLC positioning errors was investigated. Ten VMAT SBRT/SRS treatment plans were created with 6 MV FFF or 10 MV FFF beam energies using Eclipse 15.6. A MATLAB script was used to create two MLC positioning error scenarios from the original treatment plan. It was found that errors in MLC positioning were most reliably detected at 2%/1 mm for high‐resolution detectors and that lower‐resolution detectors did not consistently detect MLC positioning errors. John Wiley and Sons Inc. 2023-05-09 /pmc/articles/PMC10402672/ /pubmed/37158727 http://dx.doi.org/10.1002/acm2.14009 Text en © 2023 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, LLC on behalf of The American Association of Physicists in Medicine. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Radiation Oncology Physics
James, Shands
Al‐Basheer, Ahmad
Elder, Eric
Huh, Chulhaeng
Ackerman, Christopher
Barrett, John
Hamilton, Russell
Mostafaei, Farshad
Evaluation of commercial devices for patient specific QA of stereotactic radiotherapy plans
title Evaluation of commercial devices for patient specific QA of stereotactic radiotherapy plans
title_full Evaluation of commercial devices for patient specific QA of stereotactic radiotherapy plans
title_fullStr Evaluation of commercial devices for patient specific QA of stereotactic radiotherapy plans
title_full_unstemmed Evaluation of commercial devices for patient specific QA of stereotactic radiotherapy plans
title_short Evaluation of commercial devices for patient specific QA of stereotactic radiotherapy plans
title_sort evaluation of commercial devices for patient specific qa of stereotactic radiotherapy plans
topic Radiation Oncology Physics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402672/
https://www.ncbi.nlm.nih.gov/pubmed/37158727
http://dx.doi.org/10.1002/acm2.14009
work_keys_str_mv AT jamesshands evaluationofcommercialdevicesforpatientspecificqaofstereotacticradiotherapyplans
AT albasheerahmad evaluationofcommercialdevicesforpatientspecificqaofstereotacticradiotherapyplans
AT eldereric evaluationofcommercialdevicesforpatientspecificqaofstereotacticradiotherapyplans
AT huhchulhaeng evaluationofcommercialdevicesforpatientspecificqaofstereotacticradiotherapyplans
AT ackermanchristopher evaluationofcommercialdevicesforpatientspecificqaofstereotacticradiotherapyplans
AT barrettjohn evaluationofcommercialdevicesforpatientspecificqaofstereotacticradiotherapyplans
AT hamiltonrussell evaluationofcommercialdevicesforpatientspecificqaofstereotacticradiotherapyplans
AT mostafaeifarshad evaluationofcommercialdevicesforpatientspecificqaofstereotacticradiotherapyplans